3-[4-Methoxyphenyl]-alanine-tert-butyl ester | 101364-00-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 3-[4-Methoxyphenyl]-alanine-tert-butyl ester
• 英文别名: O-methyl-L-tyrosine t-butyl ester；tert-butyl (2S)-2-amino-3-(4-methoxyphenyl)propanoate
• CAS: 101364-00-5
• 化学式: C₁₄H₂₁NO₃
• mdl: MFCD25899557
• 分子量: 251.326
• InChiKey: HJRMJMZOUKJTDZ-LBPRGKRZSA-N

物化性质

• 沸点：
  343.8±27.0 °C(Predicted)
• 密度：
  1.063±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  18
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  61.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-[4-Methoxyphenyl]-alanine-tert-butyl ester 在 TEA 、 1-羟基苯并三唑 、 苯甲醚 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 生成 AcFTLDAD-(p-OMe-Phe)
  参考文献：
  名称：

  Toward a Rational Design of Peptide Inhibitors of Ribonucleotide Reductase:  Structure−Function and Modeling Studies

  摘要：

  Mammalian ribonucleotide reductase, a chemotherapeutic target, has two subunits, mR1 and mR2, and is inhibited by AcF(1)TLDADF(7), denoted P7. P7 corresponds to the C-terminus of mR2 and competes with mR2 for binding to mR1. We report results of a structure-function analysis of P7, obtained using a new assay measuring peptide ligand binding to mR1, that demonstrate stringent specificity for Phe at F-7, high specificity for Phe at F-1, and little specificity for the N-acyl group. They support a structural model in which the dominant interactions of P7 occur at two mR1 sites, the F-1 and F-7 subsites. The model is constructed from the structure of Escherichia colt R1 (eR1) complexed with the C-terminal peptide from eR2, aligned sequences of mR1 and eR1, and the trNOE-derived structure of mR1-bound P7. Comparison of this model with similar models constructed for mR1 complexed with other inhibitory ligands indicates that increased F-1 subsite interaction can offset lower F-7 subsite interaction and suggests strategies for the design of new, higher affinity inhibitors.

  DOI：

  10.1021/jm000335r
• 作为产物：
  描述：

  Fmoc-对甲氧基-L-苯丙氨酸 在 二乙胺 作用下， 以 二氯甲烷 、 环己烷 为溶剂， 反应 48.0h， 生成 3-[4-Methoxyphenyl]-alanine-tert-butyl ester
  参考文献：
  名称：

  Toward a Rational Design of Peptide Inhibitors of Ribonucleotide Reductase:  Structure−Function and Modeling Studies

  摘要：

  Mammalian ribonucleotide reductase, a chemotherapeutic target, has two subunits, mR1 and mR2, and is inhibited by AcF(1)TLDADF(7), denoted P7. P7 corresponds to the C-terminus of mR2 and competes with mR2 for binding to mR1. We report results of a structure-function analysis of P7, obtained using a new assay measuring peptide ligand binding to mR1, that demonstrate stringent specificity for Phe at F-7, high specificity for Phe at F-1, and little specificity for the N-acyl group. They support a structural model in which the dominant interactions of P7 occur at two mR1 sites, the F-1 and F-7 subsites. The model is constructed from the structure of Escherichia colt R1 (eR1) complexed with the C-terminal peptide from eR2, aligned sequences of mR1 and eR1, and the trNOE-derived structure of mR1-bound P7. Comparison of this model with similar models constructed for mR1 complexed with other inhibitory ligands indicates that increased F-1 subsite interaction can offset lower F-7 subsite interaction and suggests strategies for the design of new, higher affinity inhibitors.

  DOI：

  10.1021/jm000335r

文献信息

• Multiply substituted DTPA derivatives and their metal complexes, and
  申请人：Schering Aktiengesellschaft

  公开号：US05885548A1

  公开（公告）日：1999-03-23

  The invention relates to new, multiply substituted diethylenetriaminepentaacetic acid derivatives, their complexes and complex salts, that contain an element of atomic numbers 20-32, 39-51 or 57-83, pharmaceutical agents that contain these compounds, their use as contrast media and antidotes, and process for the production of pharmaceutical agents.

  该发明涉及新的、多取代的乙二胺五乙酸螯合物衍生物，其复合物和复合盐，包含原子序数为20-32、39-51或57-83的元素，含有这些化合物的药物剂，它们作为对比介质和解毒剂的用途，以及制备药物剂的过程。
• Discovery and Structure–Activity Relationships of the Neoseptins: A New Class of Toll-like Receptor-4 (TLR4) Agonists
  作者：Matthew D. Morin、Ying Wang、Brian T. Jones、Lijing Su、Murali M. R. P. Surakattula、Michael Berger、Hua Huang、Elliot K. Beutler、Hong Zhang、Bruce Beutler、Dale L. Boger

  DOI：10.1021/acs.jmedchem.6b00177

  日期：2016.5.26

  Herein, we report studies leading to the discovery of the neoseptins and a comprehensive examination of the structure–activity relationships (SARs) of this new class of small-molecule mouse Toll-like receptor 4 (mTLR4) agonists. The compounds in this class, which emerged from screening an α-helix mimetic library, stimulate the immune response, act by a well-defined mechanism (mouse TLR4 agonist), are

  在本文中，我们报道了导致新肽段的发现以及对这种新型小分子小鼠Toll样受体4（mTLR4）激动剂的结构-活性关系（SAR）的全面研究的报告。该类化合物是通过筛选α-螺旋模拟物文库而产生的，可刺激免疫反应，并通过明确的机制发挥作用（小鼠TLR4激动剂），易于生产和结构操纵，具有精美的SAR，无毒，与脂多糖相比，即使它们共享相同的受体，也能引起改善的和质上不同的反应。
• Recoverable Dendritic Phase-Transfer Catalysts that Contain (+)-Cinchonine-Derived Ammonium Salts
  作者：Jordi Rull、José Juan Jara、Rosa M. Sebastián、Adelina Vallribera、Carmen Nájera、Jean-Pierre Majoral、Anne-Marie Caminade

  DOI：10.1002/cctc.201600283

  日期：2016.6.21

  The asymmetric alkylation of a glycinate Schiff base with benzyl bromide is used as a benchmark reaction, and the dendrimeric catalyst that contains an allyl group on the O‐9 hydroxy group of the cinchonine units is the most active. The recovery and reuse of the catalyst are possible for five consecutive runs without loss of activity and with only a slight decrease in enantioselectivity. If other electrophiles

  制备了四种新的磷树枝状相转移催化剂，该催化剂在通过奎宁环烷基N原子的季铵化反应获得的表面上包含12（+）-金鸡尼盐。甘氨酸Schiff碱与苄基溴的不对称烷基化被用作基准反应，并且在辛可宁单元的O-9羟基上含有烯丙基的树枝状催化剂最为活跃。催化剂的回收和再利用可以连续进行五次，而不会损失活性，对映选择性仅略有降低。如果使用其他亲电试剂，则取代的苄基溴化物要比其他活化的烷基溴化物得到更好的结果，从而得到相应的R氨基酸衍生物。将这些结果与先前报道的类似金鸡铵盐的结果进行比较，结果表明，对于这种类型的有机催化，树状大分子可能比其他聚合物有更好的支持。
• Carboxylalkyl peptide derivatives
  申请人：G. D. Searle & Co.

  公开号：US04568666A1

  公开（公告）日：1986-02-04

  This invention encompasses novel carboxyalkyl peptide derivatives which are collagenase inhibitors.

  这项发明涵盖了一种新型的羧基烷基肽衍生物，它们是胶原酶抑制剂。
• Peptidyl calcium channel blockers
  申请人：Warner-Lambert Company

  公开号：US06423689B1

  公开（公告）日：2002-07-23

  The present invention provides compounds that block calcium channels having the Formula I shown below. The present invention also provides methods of using the compounds of Formula I to treat stroke, cerebral ischemia, head trauma, or epilepsy and to pharmaceutical compositions that contain the compounds of Formula I.

  本发明提供了阻断钙通道的化合物，其化学式如下所示：公式I。本发明还提供了使用公式I化合物治疗中风、脑缺血、头部创伤或癫痫的方法，并提供含有公式I化合物的制药组合物。